We found that the rAd.sT.GM + anti-CTLA-4 group and the triple treatment group (rAd.sT.GM + anti-PD-1 + anti-CTLA-4) are the best groups for inhibiting tumor volume during the course of the study (Figure 4A) with direct statistical comparisons of them with the buffer and other treatments shown in the table in Figure 4A. Also, on day 25, when compared with the anti-PD-1 + anti-CTLA-4 (P + C) group, only the triple treatment is significant in inhibiting tumor volume. Here, CTLA4 is linked to neoplasm.